PortalPublikationenLoss of heterozygosity at tumor suppressor genes detectable ...

Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression.

Standard

Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression. / Schwarzenbach, Heidi; Eichelser, Corinna; Kropidlowski, Jolanthe; Janni, Wolfgang; Rack, Brigitte; Pantel, Klaus.

in: CLIN CANCER RES, Jahrgang 18, Nr. 20, 20, 2012, S. 5719-5730.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schwarzenbach, H, Eichelser, C, Kropidlowski, J, Janni, W, Rack, B & Pantel, K 2012, 'Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression.', CLIN CANCER RES, Jg. 18, Nr. 20, 20, S. 5719-5730. <http://www.ncbi.nlm.nih.gov/pubmed/23014523?dopt=Citation>

APA

Schwarzenbach, H., Eichelser, C., Kropidlowski, J., Janni, W., Rack, B., & Pantel, K. (2012). Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression. CLIN CANCER RES, 18(20), 5719-5730. [20]. http://www.ncbi.nlm.nih.gov/pubmed/23014523?dopt=Citation

Vancouver

Schwarzenbach H, Eichelser C, Kropidlowski J, Janni W, Rack B, Pantel K. Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression. CLIN CANCER RES. 2012;18(20):5719-5730. 20.

Bibtex

@article{c33a9d0dadf54a28b361867fcc1bc928,
title = "Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression.",
abstract = "LOH on circulating DNA may provide tumor-specific information on breast cancer. As identification of LOH on cell-free DNA is impeded by the prevalence of wild type DNA in blood of cancer patients, we fractionated plasma DNA, and determined the diagnostic and prognostic value of both fractions.",
keywords = "Adult, Humans, Aged, Female, Middle Aged, Survival Analysis, Disease Progression, Clinical Trials as Topic, Neoplasm Staging, Kaplan-Meier Estimate, Microsatellite Repeats/genetics, Neoplastic Cells, Circulating, *Breast Neoplasms/blood/genetics/pathology, *DNA, Neoplasm/blood/genetics, Loss of Heterozygosity/*genetics, Lymphatic Metastasis/genetics/pathology, *Prognosis, Adult, Humans, Aged, Female, Middle Aged, Survival Analysis, Disease Progression, Clinical Trials as Topic, Neoplasm Staging, Kaplan-Meier Estimate, Microsatellite Repeats/genetics, Neoplastic Cells, Circulating, *Breast Neoplasms/blood/genetics/pathology, *DNA, Neoplasm/blood/genetics, Loss of Heterozygosity/*genetics, Lymphatic Metastasis/genetics/pathology, *Prognosis",
author = "Heidi Schwarzenbach and Corinna Eichelser and Jolanthe Kropidlowski and Wolfgang Janni and Brigitte Rack and Klaus Pantel",
year = "2012",
language = "English",
volume = "18",
pages = "5719--5730",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

RIS

TY - JOUR

T1 - Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression.

AU - Schwarzenbach, Heidi

AU - Eichelser, Corinna

AU - Kropidlowski, Jolanthe

AU - Janni, Wolfgang

AU - Rack, Brigitte

AU - Pantel, Klaus

PY - 2012

Y1 - 2012

N2 - LOH on circulating DNA may provide tumor-specific information on breast cancer. As identification of LOH on cell-free DNA is impeded by the prevalence of wild type DNA in blood of cancer patients, we fractionated plasma DNA, and determined the diagnostic and prognostic value of both fractions.

AB - LOH on circulating DNA may provide tumor-specific information on breast cancer. As identification of LOH on cell-free DNA is impeded by the prevalence of wild type DNA in blood of cancer patients, we fractionated plasma DNA, and determined the diagnostic and prognostic value of both fractions.

KW - Adult

KW - Humans

KW - Aged

KW - Female

KW - Middle Aged

KW - Survival Analysis

KW - Disease Progression

KW - Clinical Trials as Topic

KW - Neoplasm Staging

KW - Kaplan-Meier Estimate

KW - Microsatellite Repeats/genetics

KW - Neoplastic Cells, Circulating

KW - Breast Neoplasms/blood/genetics/pathology

KW - DNA, Neoplasm/blood/genetics

KW - Loss of Heterozygosity/genetics

KW - Lymphatic Metastasis/genetics/pathology

KW - Prognosis

KW - Adult

KW - Humans

KW - Aged

KW - Female

KW - Middle Aged

KW - Survival Analysis

KW - Disease Progression

KW - Clinical Trials as Topic

KW - Neoplasm Staging

KW - Kaplan-Meier Estimate

KW - Microsatellite Repeats/genetics

KW - Neoplastic Cells, Circulating

KW - Breast Neoplasms/blood/genetics/pathology

KW - DNA, Neoplasm/blood/genetics

KW - Loss of Heterozygosity/genetics

KW - Lymphatic Metastasis/genetics/pathology

KW - Prognosis

M3 - SCORING: Journal article

VL - 18

SP - 5719

EP - 5730

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 20

M1 - 20

ER -